News
GlobalData on MSN12h
Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight lossOrforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy.
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
In the Figure (left to right); i) cartoon representing the Rabl configuration of chromosomes in the early embryo. Pericentromeric regions are apical, chromosome arms are aligned and telomeres are ...
Novo Nordisk shares surged after Eli Lilly's weight-loss pill underperformed expectations in trial results. This setback is ...
Endocrinologists, primary care physicians (PCPs) and nurse educators perceive Lilly and Novo Nordisk to have the best diabetes corporate image, with Lilly slightly outscoring Novo among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback